

In response to the April 11, 2000 Office Action in U.S. Patent Application No. 09/430,735, please amend the application as follows:

In the title:

Replace "Blood-Brain Barrier Therapeutics" with --Method for Inducing Analgesia--.

In the claims:

Cancel claims 23-25, 51-60, 66-67, and 72.

In claim 51, replace "41" with --46-- *Sub (18)*

Amend claims 46-50 as follows:

*Sub
H₂* 46. A method for inducing analgesia in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an amphiphilic drug-oligomer conjugate comprising [enkephalin] an opioid conjugated to an oligomer, wherein the oligomer comprises [a] one or more lipophilic [moiety] moieties coupled to [a] one or more hydrophilic [moiety] moieties.

*Sub
H₂* 47. The method of claim 46 wherein the [therapeutic compound] opioid is [met⁵]enkephalin.

*Sub
C₈H₂* 48. The method of claim 46 wherein the one or more lipophilic moiety is selected from the group consisting of fatty acids, C₁₋₂₆ alkyls, and cholesterol.

*Sub
C₈H₂* 49. The method of claim 46 wherein the one or more hydrophilic moieties are selected from the group consisting of sugars and PEG.

50. The method of claim 46 wherein the one or more hydrophilic [moiety comprises] moieties comprise a sugar [and the sugar is] selected from the group consisting of amino sugars and non-amino sugars.

*Sub
H₂* 70. The method of claim 46 wherein the [therapeutic compound is an] opioid is an enkephalin.

(3) cont
Sub H2

71. The method of claim 46 wherein the [therapeutic compound is an enkephalin] opioid is a non-naturally occurring opioid.

Add the following new claims:

Sub H2

(4)

73. The method of claim 46 wherein the subject is a human.

74. The method of claim 46 wherein the amphiphilic drug-oligomer conjugate is administered orally.

75. The method of claim 46 wherein the amphiphilic drug-oligomer conjugate is administered intravenously.

76. The method of claim 46 wherein the amphiphilic drug-oligomer conjugate is administered by a route selected from the group consisting of pulmonary, intraosseal, intradermal, intramuscular, intraperitoneal, subcutaneous, intranasal and epidural.

77. The method of claim 46 wherein the amphiphilic drug-oligomer conjugate is administered by a route selected from the group consisting of intraventricular and intrathecal.

78. The method of claim 46 wherein the amphiphilic drug-oligomer conjugate is administered as a component of a pharmaceutical composition.

79. The method of claim 46 wherein the amphiphilic drug-oligomer conjugate is administered as a component of a pharmaceutical composition formulated for oral administration.

80. The method of claim 46 wherein the amphiphilic drug-oligomer conjugate is administered as a component of a pharmaceutical composition formulated for intravenous administration.

81. The method of claim 46 wherein the amphiphilic drug-oligomer conjugate is administered as a component of a pharmaceutical composition formulated for administration by a route selected from the group consisting of pulmonary, intraosseal, intradermal, intramuscular, intraperitoneal, subcutaneous, intranasal and epidural.

C4 cont
Sub
H2
cont.

82. The method of claim 46 wherein the amphiphilic drug-oligomer conjugate is administered as a component of a pharmaceutical composition formulated for administration by a route selected from the group consisting of intraventricular and intrathecal.

Not Sub

83. A method for inducing analgesia comprising administering to a subject in need thereof an analgesia-inducing amount of a cetyl-PEG₂-enkephalin conjugate.

D

84. A method for inducing analgesia comprising administering to a subject in need thereof an analgesia-inducing amount of a DHA-PEG₂-enkephalin conjugate.

D

85. The method of claim 46 wherein the oligomer ~~is~~ has a formula:



wherein n=3 to 25 and m=1 to 6.

D

86. The method of claim 46 wherein the oligomer ~~is~~ has a formula:



wherein n=3 to 25 and m=1 to 7.

D

87. The method of claim 46 wherein the oligomer ~~is~~ has a formula:



wherein n=3 to 25, m=1 to 7 and X=O or N.

D


88. The method of claim 46 wherein the oligomer ~~is~~ has a formula:



wherein m=0 to 5 and R=cholesterol or adamantine.

D

89. The method of claim 46 wherein the oligomer ~~is~~ has a formula:



(Formula 5),

wherein $m=0$ to 4 and $R=$ cholesterol or adamantane.

Sub D1


90. The method of claim 46 wherein the oligomer is has a formula:



wherein $m=0$ to 7.

Sub D1


91. The method of claim 46 wherein the oligomer is has a formula:



wherein $m=1$ to 7 and $X=N$ or O .


Sub D1

92. The method of claim 46 wherein the drug-oligomer conjugate has a formula:




Sub D1


93. The method of claim 46 wherein the drug-oligomer conjugate has a formula:




94. The method of claim 46 wherein the drug-oligomer conjugate has a formula:



95. The method of claim 46 wherein the drug-oligomer conjugate has a formula:



96. The method of claim 46 wherein the drug-oligomer conjugate has a formula:



97. The method of claim 46 wherein the drug-oligomer conjugate has a formula:

